265 related articles for article (PubMed ID: 31214875)
21. SOX9 expression decreases survival of patients with intrahepatic cholangiocarcinoma by conferring chemoresistance.
Yuan X; Li J; Coulouarn C; Lin T; Sulpice L; Bergeat D; De La Torre C; Liebe R; Gretz N; Ebert MPA; Dooley S; Weng HL
Br J Cancer; 2018 Nov; 119(11):1358-1366. PubMed ID: 30420613
[TBL] [Abstract][Full Text] [Related]
22. Repetitive response to gemcitabine that led to curative resection in cholangiocarcinoma.
Kim SH; Kim IH; Kim SW; Lee SO
World J Gastroenterol; 2009 Sep; 15(36):4593-5. PubMed ID: 19777621
[TBL] [Abstract][Full Text] [Related]
23. Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.
Sato J; Kimura T; Saito T; Anazawa T; Kenjo A; Sato Y; Tsuchiya T; Gotoh M
J Hepatobiliary Pancreat Sci; 2011 Sep; 18(5):700-11. PubMed ID: 21451941
[TBL] [Abstract][Full Text] [Related]
24. Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic marker.
Plum PS; Hess T; Bertrand D; Morgenstern I; Velazquez Camacho O; Jonas C; Alidousty C; Wagner B; Roessler S; Albrecht T; Becker J; Richartz V; Holz B; Hoppe S; Poh HM; Chia BKH; Chan CX; Pathiraja T; Teo AS; Marquardt JU; Khng A; Heise M; Fei Y; Thieme R; Klein S; Hong JH; Dima SO; Popescu I; Hoppe-Lotichius M; Buettner R; Lautem A; Otto G; Quaas A; Nagarajan N; Rozen S; Teh BT; Goeppert B; Drebber U; Lang H; Tan P; Gockel I; Schumacher J; Hillmer AM
Clin Transl Med; 2024 Jun; 14(6):e1723. PubMed ID: 38877653
[TBL] [Abstract][Full Text] [Related]
25. Therapeutic yield of extensive molecular profiling in cholangiocarcinoma: a retrospective single-center study.
Vancanneyt J; Wilmsen B; Luyten C; Verslype C; Van Cutsem E; Roskams T; Tejpar S; Vanden Bempt I; Dekervel J
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9173-9181. PubMed ID: 37184679
[TBL] [Abstract][Full Text] [Related]
26. A metabolism-related 4-lncRNA prognostic signature and corresponding mechanisms in intrahepatic cholangiocarcinoma.
Zou W; Wang Z; Wang F; Li L; Liu R; Hu M
BMC Cancer; 2021 May; 21(1):608. PubMed ID: 34034689
[TBL] [Abstract][Full Text] [Related]
27. Integrative molecular analysis of intrahepatic cholangiocarcinoma reveals 2 classes that have different outcomes.
Sia D; Hoshida Y; Villanueva A; Roayaie S; Ferrer J; Tabak B; Peix J; Sole M; Tovar V; Alsinet C; Cornella H; Klotzle B; Fan JB; Cotsoglou C; Thung SN; Fuster J; Waxman S; Garcia-Valdecasas JC; Bruix J; Schwartz ME; Beroukhim R; Mazzaferro V; Llovet JM
Gastroenterology; 2013 Apr; 144(4):829-40. PubMed ID: 23295441
[TBL] [Abstract][Full Text] [Related]
28. ACGH detects distinct genomic alterations of primary intrahepatic cholangiocarcinomas and matched lymph node metastases and identifies a poor prognosis subclass.
Jansen R; Moehlendick B; Bartenhagen C; Tóth C; Lehwald N; Stoecklein NH; Knoefel WT; Lachenmayer A
Sci Rep; 2018 Jul; 8(1):10637. PubMed ID: 30006612
[TBL] [Abstract][Full Text] [Related]
29. Narrative review: current management and novel targeted therapies in intrahepatic cholangiocarcinoma.
Bath NM; Pawlik TM
Chin Clin Oncol; 2023 Feb; 12(1):5. PubMed ID: 36922354
[TBL] [Abstract][Full Text] [Related]
30. Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ruzzenente A; Fassan M; Conci S; Simbolo M; Lawlor RT; Pedrazzani C; Capelli P; D'Onofrio M; Iacono C; Scarpa A; Guglielmi A
Ann Surg Oncol; 2016 May; 23(5):1699-707. PubMed ID: 26717940
[TBL] [Abstract][Full Text] [Related]
31. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
32. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
[TBL] [Abstract][Full Text] [Related]
33. Expression of long non-coding RNA ANRIL predicts a poor prognosis in intrahepatic cholangiocarcinoma.
Angenard G; Merdrignac A; Louis C; Edeline J; Coulouarn C
Dig Liver Dis; 2019 Sep; 51(9):1337-1343. PubMed ID: 31040073
[TBL] [Abstract][Full Text] [Related]
34. Specific prognostic factors in hepatitis B virus-related and non-hepatitis B virus-related intrahepatic cholangiocarcinoma after macroscopic curative resection.
Huang J; Wang X; Zhu Y; Wang Z; Li J; Xu D; Wang S; Li TE; Lu L
J Surg Oncol; 2019 Jan; 119(1):40-46. PubMed ID: 30480811
[TBL] [Abstract][Full Text] [Related]
35. Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.
Oliveira DV; Zhang S; Chen X; Calvisi DF; Andersen JB
Expert Rev Gastroenterol Hepatol; 2017 Apr; 11(4):349-356. PubMed ID: 28162004
[TBL] [Abstract][Full Text] [Related]
36. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins.
Tsukagoshi M; Araki K; Yokobori T; Altan B; Suzuki H; Kubo N; Watanabe A; Ishii N; Hosouchi Y; Nishiyama M; Shirabe K; Kuwano H
Oncotarget; 2017 Jun; 8(26):42159-42172. PubMed ID: 28178675
[TBL] [Abstract][Full Text] [Related]
37. A proposal of imaging classification of intrahepatic mass-forming cholangiocarcinoma into ductal and parenchymal types: clinicopathologic significance.
Rhee H; Kim MJ; Park YN; An C
Eur Radiol; 2019 Jun; 29(6):3111-3121. PubMed ID: 30560357
[TBL] [Abstract][Full Text] [Related]
38. Practical considerations in screening for genetic alterations in cholangiocarcinoma.
Bekaii-Saab TS; Bridgewater J; Normanno N
Ann Oncol; 2021 Sep; 32(9):1111-1126. PubMed ID: 33932504
[TBL] [Abstract][Full Text] [Related]
39. Enhanced expression of ten-eleven translocation 1 reverses gemcitabine resistance in cholangiocarcinoma accompanied by a reduction in P-glycoprotein expression.
Wang C; Ye H; Zhang L; Cheng Y; Xu S; Zhang P; Zhang Z; Bai J; Meng F; Zhong L; Shi G; Li H
Cancer Med; 2019 Mar; 8(3):990-1003. PubMed ID: 30784212
[TBL] [Abstract][Full Text] [Related]
40. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma.
Dong L; Lu D; Chen R; Lin Y; Zhu H; Zhang Z; Cai S; Cui P; Song G; Rao D; Yi X; Wu Y; Song N; Liu F; Zou Y; Zhang S; Zhang X; Wang X; Qiu S; Zhou J; Wang S; Zhang X; Shi Y; Figeys D; Ding L; Wang P; Zhang B; Rodriguez H; Gao Q; Gao D; Zhou H; Fan J
Cancer Cell; 2022 Jan; 40(1):70-87.e15. PubMed ID: 34971568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
